Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion.

Publication Title

The New England journal of medicine

Authors

Mayank Goyal
Johanna M Ospel
Aravind Ganesh
Dar Dowlatshahi
David Volders
Markus A Möhlenbruch
Mouhammad A Jumaa
Shahid M Nimjee
Thomas C Booth
Brian H Buck
James Kennedy
Jai J Shankar
Franziska Dorn
Liqun Zhang
Christian Hametner
Sandor Nardai
Atif Zafar
William Diprose
Shabnam Vatanpour
Alexander Stebner
Salome Bosshart
Nishita Singh
Ivy Sebastian
Kazutaka Uchida
Karla J Ryckborst
Robert Fahed
Sherry X Hu
Dominik F Vollherbst
Syed F Zaidi
Vivien H Lee
Jeremy Lynch
Jeremy L Rempel
Rachel Teal
Anurag Trivedi
Felix J Bode
Ayokunle Ogungbemi
Mirko Pham
Peter Orosz
Mohamad Abdalkader
Christian Taschner
Jason Tarpley, Pacific Neuroscience Institute, Providence, Little Company of Mary Medical Center, Torrance, CAFollow
Sven Poli
Ravinder-Jeet Singh
Reade De Leacy
George Lopez, Department of Neurology, Swedish Neuroscience Institute, Swedish Medical Center, Cherry Hill Campus, Seattle, WA USAFollow
Demetrios Sahlas
Michael Chen
Paul Burns
Joanna D Schaafsma
Richard Marigold
Arno Reich
Adewumi Amole
Thalia S Field
Richard H Swartz
Fabio Settecase
Gábor Lenzsér
Santiago Ortega-Gutierrez
Negar Asdaghi
Kyriakos Lobotesis
Adnan H Siddiqui
Joerg Berrouschot
Maxim Mokin
Koji Ebersole
Hauke Schneider
Albert J Yoo
Jennifer Mandzia
Jesse Klostranec
Changez Jadun
Tufail Patankar
Eric Sauvageau
Robert Lenthall
Lissa Peeling
Thien Huynh
Ronald Budzik
Seon-Kyu Lee
Levansri Makalanda
Michael R Levitt
Richard J Perry
Thant Hlaing
Babak S Jahromi
Paul Singh
Andrew M Demchuk
Michael D Hill
ESCAPE-MeVO Investigators

Document Type

Article

Publication Date

2-5-2025

Keywords

california; torrance; plcmmc; swedish; washington

Abstract

BACKGROUND: Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear.

METHODS: In a multicenter, prospective, randomized, open-label trial with blinded outcome evaluation, we assigned patients with acute ischemic stroke due to medium-vessel occlusion who presented within 12 hours from the time that they were last known to be well and who had favorable baseline noninvasive brain imaging to receive EVT plus usual care or usual care alone. The primary outcome was the modified Rankin scale score (range, 0 [no symptoms] to 6 [death]) at 90 days, reported as the percentage of patients with a score of 0 or 1.

RESULTS: A total of 530 patients from five countries were enrolled between April 2022 and June 2024, with 255 patients assigned to the EVT group and 275 to the usual-care group. Most patients (84.7%) had primary occlusions in a middle-cerebral-artery branch. A modified Rankin scale score of 0 or 1 at 90 days occurred in 106 of 255 patients (41.6%) in the EVT group and in 118 of 274 (43.1%) in the usual-care group (adjusted rate ratio, 0.95; 95% confidence interval [CI], 0.79 to 1.15; P = 0.61). Mortality at 90 days was 13.3% in the EVT group and 8.4% in the usual-care group (adjusted hazard ratio, 1.82; 95% CI, 1.06 to 3.12). Symptomatic intracranial hemorrhage occurred in 14 of 257 patients (5.4%) in the EVT group and in 6 of 272 (2.2%) in the usual-care group.

CONCLUSIONS: Endovascular treatment for acute ischemic stroke due to medium-vessel occlusion within 12 hours did not lead to better outcomes at 90 days than usual care. (Funded by the Canadian Institutes for Health Research and Medtronic; ESCAPE-MeVO ClinicalTrials.gov number, NCT05151172.).

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences

DOI

10.1056/NEJMoa2411668

Share

COinS